Zaretsky, J.M., et al. analyzed the whole-exome sequencing data based on matched baseline and recurrent biopsy samples from four metastatic melanoma patients who received anti-PD-1 (Pembrolizumab) and experienced initial objective regression of the tumor followed by progression months to years later. Here, PDCD1 is linked to neoplasm.